Incyte Corp.

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of patients with intermediate or high-risk myelofibrosis, for the treatment of patients with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. The company has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia.
  • TickerINCY
  • ISINUS45337C1027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 07 13

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.7x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about Monjuvi combinations, Jakafi sales growth, and their LIMBER program. Specifically, management is confident they are initiating a small trial to test their BET inhibitor and ruxolitinib combination safety and that the LIMBER program may pursue fixed-dose combinations for once-daily products. In addition, they are confident updated Monjuvi a...

INCY INCYTE CORP. (Health Care)

Incyte Corp: 1 director

A director at Incyte Corp sold 27,194 shares at 85.370USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

INCY INCYTE CORP. (Health Care)

With a more favourable environment, INCYTE improves to Slightly Positi...

INCYTE (US), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 22, 2021, the closing price was USD 85.09 and its potential was estimated at USD 95.58.

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 01 13

Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 07 13

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.7x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about Monjuvi combinations, Jakafi sales growth, and their LIMBER program. Specifically, management is confident they are initiating a small trial to test their BET inhibitor and ruxolitinib combination safety and that the LIMBER program may pursue fixed-dose combinations for once-daily products. In addition, they are confident updated Monjuvi a...

INCY INCYTE CORP. (Health Care)

Incyte Corp: 1 director

A director at Incyte Corp sold 27,194 shares at 85.370USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

INCY INCYTE CORP. (Health Care)

With a more favourable environment, INCYTE improves to Slightly Positi...

INCYTE (US), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 22, 2021, the closing price was USD 85.09 and its potential was estimated at USD 95.58.

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 01 13

Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 07 13

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.7x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about Monjuvi combinations, Jakafi sales growth, and their LIMBER program. Specifically, management is confident they are initiating a small trial to test their BET inhibitor and ruxolitinib combination safety and that the LIMBER program may pursue fixed-dose combinations for once-daily products. In addition, they are confident updated Monjuvi a...

INCY INCYTE CORP. (Health Care)

Incyte Corp: 1 director

A director at Incyte Corp sold 27,194 shares at 85.370USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

INCY INCYTE CORP. (Health Care)

With a more favourable environment, INCYTE improves to Slightly Positi...

INCYTE (US), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 22, 2021, the closing price was USD 85.09 and its potential was estimated at USD 95.58.

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 01 13

Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 07 13

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.7x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about Monjuvi combinations, Jakafi sales growth, and their LIMBER program. Specifically, management is confident they are initiating a small trial to test their BET inhibitor and ruxolitinib combination safety and that the LIMBER program may pursue fixed-dose combinations for once-daily products. In addition, they are confident updated Monjuvi a...

INCY INCYTE CORP. (Health Care)

Incyte Corp: 1 director

A director at Incyte Corp sold 27,194 shares at 85.370USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

INCY INCYTE CORP. (Health Care)

With a more favourable environment, INCYTE improves to Slightly Positi...

INCYTE (US), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 22, 2021, the closing price was USD 85.09 and its potential was estimated at USD 95.58.

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 01 13

Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 07 13

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.7x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about Monjuvi combinations, Jakafi sales growth, and their LIMBER program. Specifically, management is confident they are initiating a small trial to test their BET inhibitor and ruxolitinib combination safety and that the LIMBER program may pursue fixed-dose combinations for once-daily products. In addition, they are confident updated Monjuvi a...

INCY INCYTE CORP. (Health Care)

Incyte Corp: 1 director

A director at Incyte Corp sold 27,194 shares at 85.370USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

INCY INCYTE CORP. (Health Care)

With a more favourable environment, INCYTE improves to Slightly Positi...

INCYTE (US), a company active in the Biotechnology industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date June 22, 2021, the closing price was USD 85.09 and its potential was estimated at USD 95.58.

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Valens Research
  • Valens Research
INCY INCYTE CORP. (Health Care)

INCY - Embedded Expectations Analysis - 2021 01 13

Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch